Study Identifies Karyoptosis as a Major Driver of Brain Cell Loss in Alzheimer’s

Understanding exactly how Alzheimer's disease kills brain cells is essential for developing effective treatments. A new study has identified a previously underappreciated form of cell death, called karyoptosis, as a major contributor to neuronal loss in dementia.

Unlike better-known mechanisms such as apoptosis, karyoptosis centers on the gradual collapse of a cell's nucleus. Researchers suggest this process may account for a substantial proportion of the neuronal damage seen in Alzheimer's disease and frontotemporal dementia.

New Clues From Brain Cell Experiments

In research published in Nature Communications, scientists from King's College London examined how toxic proteins affect neurons in the laboratory. They blocked the cells' waste-disposal systems, causing disease-related proteins to accumulate, and then observed how the neurons responded.

The team identified a distinct sequence of events that ended with the disintegration of the cell nucleus. This pattern differed from the classical features of apoptosis and other well-known cell death pathways, pointing instead to karyoptosis as a separate, coordinated process.

How Karyoptosis Destroys Neurons

The researchers found that an enzyme known as p38 MAP kinase plays a central role in triggering karyoptosis. It marks LaminB1, a structural protein responsible for maintaining the shape and integrity of the nucleus, for destruction.

As LaminB1 breaks down, the nuclear scaffold collapses and the nucleus releases its contents. This structural failure ultimately leads to the death of cortical neurons, the brain cells responsible for memory, language, and decision-making.

A Potential Therapeutic Target Emerges

When the researchers blocked p38 MAP kinase in cultured neurons, toxic protein accumulation still occurred, but nuclear collapse and cell death were significantly delayed. This finding suggests that disrupting the interaction between this enzyme and LaminB1 could help slow neuronal loss.

Researchers believe that such an approach would most likely complement, rather than replace, therapies designed to reduce harmful protein accumulation. By delaying neuronal death, treatments targeting karyoptosis could potentially extend the therapeutic window for disease-modifying drugs.

Evidence From Human Dementia Brains

The team also analyzed approximately 3,000 brain cells collected from 28 people who had died with Alzheimer's disease or frontotemporal dementia. They focused on neurons from the frontal cortex, a brain region that is heavily affected in both disorders.

Signs of karyoptosis were identified in about 35% of neurons from people with dementia, compared with approximately 15% of neurons from healthy age-matched individuals. According to the researchers, these findings suggest that karyoptosis may account for a substantial proportion of neuronal degeneration in these diseases.

Implications for Future Dementia Research

Alzheimer's disease and related dementias involve multiple overlapping mechanisms of brain damage, making the development of effective treatments particularly challenging. The identification of a distinct nuclear cell death pathway offers a new direction for therapeutic development and biomarker research.

The next stage of research will involve testing experimental compounds that selectively disrupt the interaction between p38 MAP kinase and LaminB1. Scientists also plan to investigate whether biological markers of karyoptosis can be detected in living patients to help monitor disease progression and treatment response.

With more than 55 million people worldwide living with dementia, even modest success in slowing neuronal death could translate into additional years of preserved independence for many patients. The findings highlight how a deeper understanding of fundamental cellular processes may ultimately contribute to more effective, targeted treatments for neurodegenerative diseases.